Adlai Nortye to Showcase Innovative Cancer Therapy at Key Conference

Author: Logan Wright Updated: 10-13-2025 11:28 PM

Adlai Nortye's Participation in an International Conference

Adlai Nortye Ltd. (NASDAQ: ANL), a forward-thinking biotechnology firm dedicated to pioneering cancer therapies, has announced its participation in a prestigious international conference focused on molecular targets and cancer treatments. This significant event will take place in Boston from October 22-26 in 2025, marking an important milestone for the company.

Details of the Presentation

During this conference, the company will present an oral talk focusing on their latest research. This is an incredible opportunity for Adlai Nortye to share its advancements directly with key industry leaders and peers.

Key Presentation Information

The details of the presentation are as follows:

Abstract Title: Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate (ADC) armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window.

Date and Time: Saturday, October 25, from 11:45 AM to 12:15 PM ET.

Session Title: Spotlight on Proffered Papers 3: Novel Therapeutic Agents.

About the Innovative AN4035

A focal point of the presentation will be AN4035, an innovative ADC designed to target CEACAM5 while utilizing a pan-RAS(ON) inhibitor to extend treatment efficacy for patients. This groundbreaking approach is indicative of Adlai Nortye's commitment to developing therapies that offer improved outcomes for cancer patients.

Upcoming Insights on AN4035

On October 22, 2025, prior to the presentation, the cornerstone data surrounding AN4035 will become available on the AACR portal. This release is anticipated to provide insights into the scientific rationale behind AN4035, thereby setting the stage for a deeper understanding of this therapeutic approach.

Overview of Adlai Nortye

Operating on a global scale, Adlai Nortye focuses on the development and commercialization of cancer therapies through its extensive R&D centers in both the U.S. and China. Their product pipeline is robust, with significant advancements in therapies that modulate immune responses and target RAS-driven cancers.

Innovative Drug Portfolio

The company is advancing a variety of innovative drug candidates, which includes their notable compounds: AN8025, a multifunctional protein targeting PD-1/L1, and AN4005, a unique oral small-molecule PD-L1 inhibitor. These therapies are designed to improve the treatment landscape for patients facing a myriad of cancer types.

Company Contact Information

For inquiries regarding the presentation or other corporate matters, you may contact Adlai Nortye's Investor Relations at Email: ir@adlainortye.com.

Frequently Asked Questions

What is the AACR-NCI-EORTC conference?

The AACR-NCI-EORTC conference is an influential international event focused on the latest developments in cancer research and therapeutic innovations.

What is AN4035?

AN4035 is a novel antibody-drug conjugate designed to target CEACAM5 and is equipped with a proprietary pan-RAS(ON) inhibitor payload.

When will Adlai Nortye present?

The company will present on October 25 from 11:45 AM to 12:15 PM ET during the conference.

How can I follow the updates on Adlai Nortye?

You can obtain updates by following their official announcements and releases shared prior to significant events.

Where are Adlai Nortye's R&D centers located?

The company's R&D centers are located in the United States and China, enabling a broad scope for discovery and development.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.